Cite
HARVARD Citation
Mok, T. et al. (n.d.). LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations. Annals of oncology. p. . [Online].